New SARS-CoV-2 strain identified in South East England
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
List view / Grid view
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Scientists have trained a computer algorithm to identify differences in cancer cell lines based on microscopic images, preventing the misclassification of cells.
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Two drugs, Nefiracetam and PHA 543613, were able to return neuronal signalling to near normal in organoids derived from patients with the autism spectrum disorder, Rett syndrome.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
Elevated levels of a biomarker related to blood vessel damage have been found in all children with SARS-CoV-2 infection.
A long-term study of macaques given mitochondrial replacement therapy (MRT) found that both treated individuals and their offspring were healthy and developed normally.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Next-generation sequencing will be employed to study 1,500 plasma proteins in participants, according to UK Biobank.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
Researchers show that neutralising antibodies targeting the SARS-CoV-2 Spike protein have four distinct structures.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.